Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (27)

2024

  1. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

    Journal of Clinical Medicine, Vol. 13, Núm. 9

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  3. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

    Journal of Clinical Medicine, Vol. 12, Núm. 2

  4. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

    Frontiers in Endocrinology, Vol. 14

2022

  1. Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry

    Journal of the American Heart Association, Vol. 11, Núm. 13

  2. Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 2, pp. 202-210

  3. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

    International Journal of Clinical Practice, Vol. 2022

  4. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

    Cardiology Journal, Vol. 29, Núm. 6, pp. 936-947

  5. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  6. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

  7. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 1, pp. 4-11

2021

  1. Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19])

    Critical Care Medicine, Vol. 49, Núm. 6, pp. E624-E633

  2. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 608-615

  3. COVID-19 and the impact of arterial hypertension—An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany)

    European Journal of Clinical Investigation, Vol. 51, Núm. 11

  4. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

    Infection, Vol. 49, Núm. 4, pp. 677-684

  5. Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction

    Journal of the American College of Cardiology, Vol. 78, Núm. 7, pp. 643-662

  6. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19

    European Journal of Clinical Investigation, Vol. 51, Núm. 1

  7. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

    Internal and Emergency Medicine, Vol. 16, Núm. 4, pp. 957-966

  8. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

    American Heart Journal, Vol. 237, pp. 104-115